GI Dynamics is pioneering the development of effective, non-surgical approaches for treating type 2 diabetes and obesity. The EndoBarrier^® Gastrointestinal Liner (the EndoBarrier) is implanted in the initial parts of the intestine, mimicking the effects of gastric bypass surgery, without the risks associated with surgery. Data from more than 500 patients demonstrate that the EndoBarrier is a safe and effective treatment for type 2 diabetes and/or obesity, providing rapid improvement in glucose control and significant weight loss during the implant period. The EndoBarrier is commercially available in select markets in Europe and South America, and it has received TGA approval and will soon be available in Australia.

Through our patented EndoBarrier platform of technologies, GI Dynamics is poised to address one of the largest global healthcare markets. We have significant clinical experience, a highly differentiated product profile, the backing of major investors, including Johnson & Johnson Development Corporation, ATV Associates, Polaris, Domain Associates, Cutlass Capital and Medtronic, Inc., and some of the brightest technical and clinical minds in the industry.